Home



We invest to accelerate the development of near term, promising products that address unmet medical needs of people with autism, epilepsy and schizophrenia.



We invest to accelerate the development of near term, promising products that address unmet medical needs of people with autism, epilepsy and schizophrenia.



We invest to accelerate the development of near term, promising products that address unmet medical needs of people with autism, epilepsy and schizophrenia.



We invest to accelerate the development of near term, promising products that address unmet medical needs of people with autism, epilepsy and schizophrenia.



We invest to accelerate the development of near term, promising products that address unmet medical needs of people with autism, epilepsy and schizophrenia.

previous arrow
next arrow
Slider

Identify

We identify new products, therapeutics or diagnostics for patients with serious neurological disorders including autism, epilepsy and schizophrenia.

Invest

We invest in companies or form companies that are translating research into products. By bridging the gap between research and product development, we help these companies become attractive to later stage VCs and Pharma who can take them to market.

Partner

We work in partnership with both research institutions and companies.

Turning neurodisorder research into marketable products needs to happen faster. NNF focuses on accelerating time to market for much needed drugs, diagnostics and other medical products for patients with serious neurological disorders including autism, epilepsy and schizophrenia. Venture capital and philanthropy are complementary. Each seeks to identify and nurture exciting innovation. Both hope to realize gains in the advancement of medical knowledge. By combining venture capital and philanthropy, NNF aims to close the gap between innovative research that can lead to ground-breaking products and the companies that bring products to market.

Our initial focus on autism, epilepsy and schizophrenia allows us to leverage the new scientific commonality between various conditions once thought to be unrelated. Shared genetic and biochemical pathways give rise to distinctive and potentially overlapping clinical conditions. Basic innovative research is already generating novel insights and innovative technology is waiting to be translated into marketable products. The traditional actors who translate the research into products, the early stage VCs who finance start-up biotechs, are disappearing. As a not-for-profit organization, all investment returns will be reinvested and deployed to support additional projects and novel research to become products that can make a difference.

Neuronetworks Fund
27 Pine Street-Suite 600
New Canaan, CT 06840

NNF is a 501 (c)(3) non-profit organization; all donations are tax-deductible.

EIN: 46-4189615